This is single dose study of radiolabeled \[14C\]-ertugliflozin (PF04971729, MK-8835) in healthy male volunteers to study the absorption, distribution, metabolism and elimination of ertugliflozin.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
6
Ertugliflozin 25 mg will be administered as a single oral suspension containing approximately 100 uCi of \[14C\]ertugliflozin
Mean Percent of Dose Recovered in Urine and Feces Following a Single Oral Dose of [^14C]Ertugliflozin (100 µCi).
Time frame: Up to 7 Days
Area under the plasma concentration-time curve (AUC) from time 0 to time of the last quantifiable concentration (AUClast) for ertugliflozin
Time frame: Up to 7 Days
AUC from Hour 0 to infinity (AUCinf) for ertugliflozin
Time frame: Up to 7 Days
Maximum plasma concentration (Cmax) of ertugliflozin
Time frame: Up to 7 Days
Time taken to reach the maximum observed plasma concentration (Tmax) of ertugliflozin
Time frame: Up to 7 Days
Ertugliflozin half life (t1/2)
Time frame: Up to 7 Days
Amount of Ertugliflozin and metabolites in plasma, urine, and feces
Time frame: Up to 7 Days
Number of Participants Experiencing an Adverse Event (AE)
Time frame: Up to 7 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.